News
MNOV
1.395
-0.36%
-0.005
MediciNova (MNOV) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 2d ago
Weekly Report: what happened at MNOV last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at MNOV last week (1026-1030)?
Weekly Report · 11/02 09:44
Weekly Report: what happened at MNOV last week (1019-1023)?
Weekly Report · 10/26 09:44
Weekly Report: what happened at MNOV last week (1012-1016)?
Weekly Report · 10/19 09:44
MediciNova CEO provides update on results from Phase 2 trial of MN-001
TipRanks · 10/12 10:16
MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance
Benzinga · 10/12 10:07
Weekly Report: what happened at MNOV last week (1005-1009)?
Weekly Report · 10/12 09:47
MediciNova to Participate in the Maxim Growth Summit
Barchart · 10/06 05:00
Weekly Report: what happened at MNOV last week (0928-1002)?
Weekly Report · 10/05 09:46
Major Investor Makes a Big Exit Move in Medicinova
TipRanks · 09/30 02:01
MediciNova Extends Office Lease, Signals Long-Term Stability
TipRanks · 09/28 21:12
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 09/28 17:06
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
Benzinga · 09/28 15:10
Analysts Are Bullish on Top Healthcare Stocks: Medicinova (MNOV), AbbVie (ABBV)
TipRanks · 09/28 15:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 09/28 12:05
MediciNova Stock Falls on Topline Results from Phase 2 Trial for Fatty Liver Disease Treatment
Dow Jones · 09/28 11:15
MediciNova Reports Phase 2 MN-001 Data In T2DM-Associated NAFLD; Stock Plunges In Premarket
NASDAQ · 09/28 10:49
MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant
Benzinga · 09/28 10:15
MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001
TipRanks · 09/28 10:15
More
Webull provides a variety of real-time MNOV stock news. You can receive the latest news about Medicinova through multiple platforms. This information may help you make smarter investment decisions.
About MNOV
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.